Jeil Pharma Holdings제일파마홀딩스
002620 · KOSPI · ₩002620 · 제일파마홀딩스
₩6,780▼ ₩120 (1.74%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 40.7% | 38.5% | 26.5% | 26.7% | 22.8% | 23.7% |
| Operating margin | 2.9% | 5.9% | −1.5% | 2.6% | −1.0% | −1.2% |
| Net margin | 1.3% | 2.2% | −6.6% | −2.0% | −9.4% | −0.5% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −4.1% | −15.7% | −3.0% | +1.4% | +4.0% | — |
| Operating income growth | −52.8% | +434.7% | −155.5% | +375.8% | +15.9% | — |
| Net income growth | −42.4% | +128.6% | −214.8% | +78.2% | −2,040.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | 2.7% | 4.7% | −16.3% | −4.9% | −19.9% | −0.8% |
| Return on assets | 2.9% | 3.9% | −7.5% | −1.5% | −9.5% | −1.4% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 89.5% | 86.9% | 103.6% | 118.8% | 106.2% | 78.4% |
| Net debt to equity | −13.0% | 19.7% | −14.6% | 24.4% | 23.8% | 16.8% |
| Current ratio | 120.1% | 115.5% | 108.4% | 93.2% | 98.4% | 112.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Jeil Pharma Holdings / 제일파마홀딩스 / 002620 / KRX:002620
Source: KRX statistical information